Amgen invests $300M into U.S. manufacturing capabilites
Thousand Oaks-based Amgen continues to invest in its onshore capabilities, after the biotech giant announced plans to invest an additional $300 million in its U.S. manufacturing network to further expand U.S.-based production capacity.
Announced May 4, Amegn plans to expand its biologics manufacturing facility in Puerto Rico, which will strengthen existing advanced manufacturing roles, support workforce development across the region and generate hundreds of construction jobs.
Established in 1992, the company’s Juncos site is one of the largest and most advanced biomanufacturing facilities in the world, producing biologic medicines distributed to more than 60 countries.
“Amgen has been a leader in U.S. biomanufacturing for decades, and this expansion reflects our continued commitment to American manufacturing,” said Robert A. Bradway, chairman and chief executive officer at Amgen. “By growing our operations in Puerto Rico, we are ensuring patients have access to the medicines they need, investing in the long-term strength of our domestic supply chain and supporting American jobs.”
Over the past year, the company has announced planned investments of $650 million in Puerto Rico, $900 million in Ohio and $600 million in a science and innovation center in California. In addition, Amgen has invested more than $1.5 billion in North Carolina.
